Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant NAI, Sotevtamab, and Zabadinostat with Chemotherapy in Pancreatic Cancer
NCT07488884Phase 1Withdrawn
- Sponsor
- ImmunityBio, Inc.
- Start
- Sep 2026
- Primary completion
- Jun 2027
- Modality
- Small Molecules, Cytokines & Interferons, Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of nogapendekin alfa inbakicept, sotevtamab and zabadinostat in pancreatic ductal adenocarcinoma (PDAC), sponsored by ImmunityBio, Inc. Primary endpoints: Treatment-Emergent Adverse Events and Serious Adverse Events at 104 weeks and Clinically important changes in laboratory tests and vital signs at 104 weeks. Planned start Sep 2026; status: withdrawn.
02
Drugs
nogapendekin alfa inbakiceptsotevtamabzabadinostat
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07488884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07488884.